Cwm, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Cwm, LLC holds 6,764 shares of ALNY stock, worth $1.64 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

6,764

Previous 3,492 93.7%

Holding current value

$1.64 Million

Previous $849,000 119.08%

% of portfolio

0.01%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$233.81 - $287.01 $765,026 - $939,096	3,272 Added 93.7%	6,764 $1.86 Million
Q2 2024 Jul 09, 2024	BUY	$143.31 - $247.0 $253,658 - $437,190	1,770 Added 102.79%	3,492 $849,000
Q1 2024 Apr 05, 2024	SELL	$146.51 - $198.2 $6.11 Million - $8.26 Million	-41,678 Reduced 96.03%	1,722 $257,000
Q4 2023 Feb 01, 2024	SELL	$151.41 - $196.57 $81,458 - $105,754	-538 Reduced 1.22%	43,400 $8.31 Million
Q3 2023 Oct 11, 2023	SELL	$170.77 - $211.65 $245,225 - $303,929	-1,436 Reduced 3.16%	43,938 $7.78 Million
Q2 2023 Aug 03, 2023	BUY	$185.01 - $212.05 $8.08 Million - $9.26 Million	43,648 Added 2528.85%	45,374 $8.62 Million
Q1 2023 Apr 28, 2023	SELL	$182.66 - $235.53 $35,253 - $45,457	-193 Reduced 10.06%	1,726 $346,000
Q4 2022 Feb 01, 2023	SELL	$185.53 - $241.31 $193,693 - $251,927	-1,044 Reduced 35.23%	1,919 $456,000
Q3 2022 Oct 27, 2022	SELL	$138.54 - $232.0 $56,801 - $95,120	-410 Reduced 12.16%	2,963 $593,000
Q2 2022 Jul 28, 2022	SELL	$120.42 - $169.29 $792,243 - $1.11 Million	-6,579 Reduced 66.11%	3,373 $492,000
Q1 2022 Apr 21, 2022	SELL	$127.18 - $173.91 $260,210 - $355,819	-2,046 Reduced 17.05%	9,952 $1.63 Million
Q4 2021 Jan 31, 2022	BUY	$159.56 - $209.29 $16,275 - $21,347	102 Added 0.86%	11,998 $2.04 Million
Q1 2021 Sep 15, 2021	BUY	$126.83 - $175.69 $1.41 Million - $1.95 Million	11,096 Added 1387.0%	11,896 $2.02 Million
Q1 2021 Apr 27, 2021	SELL	$126.83 - $175.69 $1.41 Million - $1.95 Million	-11,096 Reduced 93.28%	800 $113,000
Q4 2020 Sep 15, 2021	BUY	$122.97 - $147.0 $1.38 Million - $1.65 Million	11,196 Added 1599.43%	11,896 $2.02 Million
Q4 2020 Jan 27, 2021	SELL	$122.97 - $147.0 $1.38 Million - $1.65 Million	-11,196 Reduced 94.12%	700 $91,000
Q3 2020 Sep 15, 2021	BUY	$121.19 - $165.49 $1.36 Million - $1.86 Million	11,246 Added 1730.15%	11,896 $2.02 Million
Q3 2020 Oct 19, 2020	SELL	$121.19 - $165.49 $1.36 Million - $1.86 Million	-11,246 Reduced 94.54%	650 $95,000
Q2 2020 Sep 15, 2021	BUY	$104.21 - $156.44 $1.17 Million - $1.76 Million	11,240 Added 1713.41%	11,896 $2.02 Million
Q2 2020 Jul 22, 2020	SELL	$104.21 - $156.44 $1.17 Million - $1.76 Million	-11,240 Reduced 94.49%	656 $97,000
Q1 2020 Sep 15, 2021	BUY	$93.12 - $133.99 $1.06 Million - $1.52 Million	11,346 Added 2062.91%	11,896 $2.02 Million
Q1 2020 Apr 28, 2020	SELL	$93.12 - $133.99 $1.06 Million - $1.52 Million	-11,346 Reduced 95.38%	550 $60,000
Q4 2019 Sep 14, 2021	BUY	$74.51 - $124.23 $842,782 - $1.41 Million	11,311 Added 1933.5%	11,896 $2.02 Million
Q4 2019 Jan 27, 2020	SELL	$74.51 - $124.23 $842,782 - $1.41 Million	-11,311 Reduced 95.08%	585 $67,000
Q3 2019 Sep 14, 2021	BUY	$70.9 - $87.82 $801,949 - $993,332	11,311 Added 1933.5%	11,896 $2.02 Million
Q3 2019 Oct 22, 2019	SELL	$70.9 - $87.82 $801,949 - $993,332	-11,311 Reduced 95.08%	585 $47,000
Q2 2019 Sep 14, 2021	BUY	$65.86 - $92.79 $781,165 - $1.1 Million	11,861 Added 33888.57%	11,896 $2.02 Million
Q2 2019 Jul 31, 2019	SELL	$65.86 - $92.79 $781,165 - $1.1 Million	-11,861 Reduced 99.71%	35 $3,000
Q1 2019 Sep 02, 2021	BUY	$72.76 - $93.45 $865,552 - $1.11 Million	11,896 New	11,896 $0

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account